University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor
Print this page
FONT SIZE
Home > Doctors > Jonathan P. Terdiman

Jonathan P. Terdiman, M.D.

Gastroenterologist

Dr. Jonathan Terdiman is co-director of the Center for Inflammatory Bowel Disease and the Colorectal Cancer Prevention Program at UCSF Medical Center. His research interests include colorectal cancer prevention, hereditary gastrointestinal cancer and inflammatory bowel disease. He frequently lectures in the community, at the university and for various professional organizations on these subjects.

Terdiman earned a medical degree at Columbia University, College of Physicians and Surgeons. He went on to complete a residency in internal medicine and fellowships in critical care medicine and gastroenterology at UCSF, where he is a professor of clinical medicine and surgery.

Clinics

Gastroenterology at Mount Zion
2330 Post St., Suite 610
San Francisco, CA 94115
Phone: (415) 502-4444
Fax: (415) 502-2249

Hours: Monday to Friday
9 a.m. – 4:30 p.m.

Inflammatory Bowel Disease Center
2330 Post St., Sixth Floor
San Francisco, CA 94115
Phone: (415) 502-4444
Fax: (415) 502-2249

Cancer Risk Program
1600 Divisadero St., Second Floor
San Francisco, CA 94143-1714
Phone: (415) 885-7779
Fax: (415) 885-3787

Hours: Monday to Friday
9 a.m. – 5 p.m.

Conditions & Treatments

More about Jonathan P. Terdiman

Education

Columbia University School of Medicine 1989

Residencies

UCSF Medical Center, Internal Medicine 1992

Fellowships

UCSF Medical Center, Gastroenterology 1996

Selected Research and Publications

  1. Yurgelun MB, Mercado R, Rosenblatt M, Dandapani M, Kohlmann W, Conrad P, Blanco A, Shannon KM, Chung DC, Terdiman J, Gruber SB, Garber JE, Syngal S, Stoffel EM. Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome. Gynecol Oncol. 2012 Dec; 127(3):544-51.
  2. Kuppermann M, Wang G, Wong S, Blanco A, Conrad P, Nakagawa S, Terdiman J, Ladabaum U. Preferences for outcomes associated with decisions to undergo or forgo genetic testing for Lynch syndrome. Cancer. 2013 Jan 1; 119(1):215-25.
  3. Katz L, Gisbert JP, Manoogian B, Lin K, Steenholdt C, Mantzaris GJ, Atreja A, Ron Y, Swaminath A, Shah S, Hart A, Lakatos PL, Ellul P, Israeli E, Svendsen MN, van der Woude CJ, Katsanos KH, Yun L, Tsianos EV, Nathan T, Abreu M, Dotan I, Lashner B, Brynskov J, Terdiman JP, Higgins PD, Chaparro M, Ben-Horin S. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis. 2012 Nov; 18(11):2026-33.
  4. Larsen M, Hills N, Terdiman J. The impact of the quality of colon preparation on follow-up colonoscopy recommendations. Am J Gastroenterol. 2011 Dec; 106(12):2058-62.
  5. Lin KK, Velayos F, Fisher E, Terdiman JP. Durability of infliximab dose intensification in Crohn's disease. Dig Dis Sci. 2012 Apr; 57(4):1013-9.
  6. Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, Ford J, Elkin E, Phillips KA. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. 2011 Jul 19; 155(2):69-79.
  7. Khan O, Blanco A, Conrad P, Gulden C, Moss TZ, Olopade OI, Kupfer SS, Terdiman J. Performance of Lynch syndrome predictive models in a multi-center US referral population. Am J Gastroenterol. 2011 Oct; 106(10):1822-7; quiz 1828.
  8. Terdiman JP. The prevention of colitis-related cancer by 5-aminosalicylates: an appealing hypothesis that remains unproven. Am J Gastroenterol. 2011 Apr; 106(4):737-40.
  9. Day LW, Espey DK, Madden E, Segal M, Terdiman JP. Screening prevalence and incidence of colorectal cancer among American Indian/Alaskan natives in the Indian Health Service. Dig Dis Sci. 2011 Jul; 56(7):2104-13.
  10. Terdiman JP, McQuaid KR. Surveillance guidelines should be updated to recognize the importance of serrated polyps. Gastroenterology. 2010 Nov; 139(5):1444-7.
  11. El-Nachef N, Terdiman J, Mahadevan U. Anti-tumor necrosis factor therapy for inflammatory bowel disease in the setting of immunosuppression for solid organ transplantation. Am J Gastroenterol. 2010 May; 105(5):1210-1.
  12. Stoffel EM, Mercado RC, Kohlmann W, Ford B, Grover S, Conrad P, Blanco A, Shannon KM, Powell M, Chung DC, Terdiman J, Gruber SB, Syngal S. Prevalence and predictors of appropriate colorectal cancer surveillance in Lynch syndrome. Am J Gastroenterol. 2010 Aug; 105(8):1851-60.
  13. Burt RW, Barthel JS, Dunn KB, David DS, Drelichman E, Ford JM, Giardiello FM, Gruber SB, Halverson AL, Hamilton SR, Ismail MK, Jasperson K, Lazenby AJ, Lynch PM, Martin EW, Mayer RJ, Ness RM, Provenzale D, Rao MS, Shike M, Steinbach G, Terdiman JP, Weinberg D. NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw. 2010 Jan; 8(1):8-61.
  14. Terdiman JP, Johnson LK, Kim YS, Sleisenger MH, Gum JR, Hayes A, Weinberg VK, McQuaid KR. Chemoprevention of colonic polyps with balsalazide: an exploratory, double-blind, placebo-controlled study. Dig Dis Sci. 2009 Nov; 54(11):2488-96.
  15. Terdiman JP. MYH-associated disease: attenuated adenomatous polyposis of the colon is only part of the story. Gastroenterology. 2009 Dec; 137(6):1883-6.
  16. Grover S, Stoffel EM, Mercado RC, Ford BM, Kohlman WK, Shannon KM, Conrad PG, Blanco AM, Terdiman JP, Gruber SB, Chung DC, Syngal S. Colorectal cancer risk perception on the basis of genetic test results in individuals at risk for Lynch syndrome. J Clin Oncol. 2009 Aug 20; 27(24):3981-6.
  17. Nguyen SP, Bent S, Chen YH, Terdiman JP. Gender as a risk factor for advanced neoplasia and colorectal cancer: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009 Jun; 7(6):676-81.e1-3.
  18. Wang JY, Terdiman JP, Vittinghoff E, Minichiello T, Varma MG. Hospitalized ulcerative colitis patients have an elevated risk of thromboembolic events. World J Gastroenterol. 2009 Feb 28; 15(8):927-35.
  19. Li D, Jin C, McCulloch C, Kakar S, Berger BM, Imperiale TF, Terdiman JP. Association of large serrated polyps with synchronous advanced colorectal neoplasia. Am J Gastroenterol. 2009 Mar; 104(3):695-702.
  20. Shergill AK, Terdiman JP. The early use of immunosuppression reduces morbidity in patients with moderately severe or severe Crohn's disease. Gastroenterology. 2008 Oct; 135(4):1417-20.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.

Home • Terms of Use • Site Map • Contact Us       © 2002 - 2013 The Regents of The University of California